Physician profile
Ashok Kumar Sinha
NPI 1073675641
$4,371.91
in general payments reported to CMS, 2019-2025
40 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $810 · 2021: $892 · 2022: $520 · 2023: $641 · 2024: $364 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.29 | 2019-2024 | Farxiga, Fasenra, Airsupra |
| Novo Nordisk INC | $597.32 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $476.63 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $334.03 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $312.79 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $212.04 | 2019-2021 | |
| Glaxosmithkline, LLC. | $199.75 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $176.61 | 2020-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.81 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Optinose US, INC. | $123.72 | 2020-2022 | |
| Eisai INC. | $113.80 | 2020-2021 | |
| Astellas Pharma US INC | $107.97 | 2019-2025 | Veozah |
| Genentech USA, INC. | $79.81 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $75.11 | 2019-2023 | |
| Orexo US, INC. | $70.91 | 2019-2023 | Zubsolv |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.